NEW YORK — Cancer Genetics on Wednesday reported a nearly threefold jump in its third quarter revenues on a strong performance by its core discovery services operations.
For the three-month period ended Sept. 30, Cancer Genetics' revenues climbed to $2.1 million from $535,000 in the same period a year earlier. The revenues were generated entirely by discovery services, which includes contract research for cancer and immuno-oncology drug discovery and development.